Search Results
Your search for ,WHo matches 20837 pages
Showing 6251 - 6300A Junior High School Teacher Sparks a Love for Science
Peter Marks, MD, PhD, Director of the U.S. Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER), was born in Brooklyn, New York, near Sheepshead Bay—an area named for the Sheepshead, a fish that can no longer be found in the waters that frame the neighborhood....
After a Flirtation With Infectious Disease, Hematology Calls, Leading to a Notable Career
High-quality cancer care is a complex mixture of science and art, made even more challenging by the dizzying array of coding, billing, and data collection regulations that must be taken into account. Synthesizing all the parts into value-based, whole-patient care across the wide spectrum of the...
A Pioneer in Head and Neck Cancer Surgery Whose Career Was Founded on Passion and Dedication
The term “head and neck surgery” had little meaning until the 1940s, when it was used by groundbreaking surgeon Hayes Martin, MD, in one of his publications. Dr. Martin was then Chief of Head and Neck Services at Memorial Hospital, later renamed Memorial Sloan Kettering Cancer Center (MSK), where...
A Career in Cardio-oncology Founded on Simple Principles Taught by Her Immigrant Parents
Cardio-oncology focuses on the detection, monitoring, and treatment of cardiovascular disease occurring secondary to cancer treatment, and the mechanistic and epidemiologic intersection between cardiovascular disease and cancer. With the advent of targeted agents and immunotherapies,...
Serendipity Plays a Role in a Journey to a Noted Career in Surgical Oncology
Over the past 2 decades, the oncologic mantra “early detection leads to cure” has taken on special meaning in lung cancer, persistently a leading cause of cancer death in the United States. “Over a 25-year period, we’ve seen a revolution in early detection, understanding of tumor biology, and...
A Pioneer in Geriatric Oncology Leaves His Mark and Marches Forward
The field of geriatric oncology has developed steadily over the past several decades, thanks to the dedication of a close-knit community of oncologists who have devoted their careers to advancing multidisciplinary care for older patients with cancer. One such leader is Silvio Monfardini, MD, past...
A Brooklyn Girl Bucks Her Old-Fashioned Upbringing to Become a Leader in Bone Marrow Transplantation
In the face of old school mores, self-motivation and perseverance were needed to build a career as a nationally regarded blood and bone marrow transplant expert. “I was born and reared in Brooklyn, New York, the oldest of seven children of Irish-Italian parents who did not espouse professional...
A Junior High School Teacher Sparks a Love for Science
Peter Marks, MD, PhD, Director of the U.S. Food and Drug Administration (FDA)’s Center for Biologics Evaluation and Research (CBER), was born in Brooklyn, New York, near Sheepshead Bay—an area named for the Sheepshead, a fish that can no longer be found in the waters that frame the neighborhood....
A Doctor’s Daughter Becomes a Pioneer in Cancer Survivorship
Although quality of life has been an implicit medical outcome since the time of Hippocrates, integrating the explicit effort to assess the effects of cancer treatment on the patient’s quality—and not quantity—of life was spearheaded by dedicated pioneers. One such trailblazer is Patricia A. Ganz,...
New FDA-Approved Oncology Drugs and Label Updates Between May 8, 2020, and May 8, 2021
Over the past year (May 2020–May 2021), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers and adverse events. The new approvals and accelerated approvals are listed below. PEMBROLIZUMAB (KEYTRUDA) in...
A Love for Surgery Underpins a Career Devoted to Patients With Pancreatic Cancer
There are few, if any, more difficult clinical challenges than pancreatic cancer, a disease that continues to confound the oncology community’s quest for cure. Yet, incremental progress and unflagging optimism drive the way forward, thanks to the researchers and clinicians who have dedicated their...
Organizations Issue Statement Encouraging Return to HPV Vaccination
Doctors and scientists across America at National Cancer Institute (NCI)-designated cancer centers and other organizations recently issued a joint statement urging the nation’s health-care systems, physicians, parents, children, and young adults to get human papillomavirus (HPV) vaccination back on ...
Study Examines Barriers to Survivorship Care
Even among a large group of cancer survivors who were mostly insured, college-educated, and had annual incomes above the national average, up to 10% delayed care in the previous 12 months because they simply could not afford out-of-pocket expenses like copays and deductibles. These findings were...
Third-Party BK Virus–Specific Cytotoxic T-Lymphocyte Therapy for BK Virus–Associated Hemorrhagic Cystitis After Stem Cell Transplant
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Olson et al found that high rates of response were achieved with third-party BK virus–specific cytotoxic T-lymphocyte therapy (BKV-CTL) in patients with BK virus–associated hemorrhagic cystitis after allogeneic...
Noninvasive Imaging Biomarker and Pathologic Complete Response to Neoadjuvant Pertuzumab/Trastuzumab in HER2-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Roisin M. Connolly, MD, and colleagues, updated results of the phase II TBCRC026 trial indicate an association of early F-18 fluorodeoxyglucose positron-emission tomography/computed tomography (F-18 FDG PET/CT) maximum standardized uptake value...
Real-World Survival Outcomes With Various Treatment Regimens for Metastatic Renal Cell Carcinoma
In a real-world retrospective propensity-matched cohort study reported in JAMA Network Open, Chakiryan et al found that both first-line immunotherapy and combined treatment with targeted therapy plus immunotherapy were associated with improved overall survival vs targeted therapy alone in patients...
Pembrolizumab in BCG-Unresponsive High-Risk Non–Muscle Invasive Bladder Cancer: KEYNOTE-057
As reported in The Lancet Oncology by Arjun V. Balar, MD, and colleagues, the phase II KEYNOTE-057 trial showed that pembrolizumab produced enduring responses in a cohort of patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG) who were ineligible ...
Neoadjuvant Chemotherapy De-escalation Using F-18 FDG-PET Response–Based Strategy in HER2-Positive Breast Cancer
In the European phase II PHERGain study reported in The Lancet Oncology, Pérez-García et al found that an F-18 fluorodeoxyglucose positron-emission tomography (F-18 FDG-PET) response–based strategy may be able to identify patients with HER2-positive early breast cancer who may benefit from...
FDA Approves Sotorasib for KRAS G12C–Mutated NSCLC
On May 28, the U.S. Food and Drug Administration (FDA) approved sotorasib (Lumakras) as the first treatment for adult patients with non–small cell lung cancer (NSCLC) whose tumors have a KRAS G12C genetic mutation and who have received at least one prior systemic therapy. This is the first approved ...
New Approaches Needed for Patients With Locoregional Breast Cancer Progression During Neoadjuvant Systemic Therapy
Patients with breast cancer who experience disease progression on neoadjuvant systemic therapy tend to have poor survival outcomes, even after surgical management, according to a study presented during the 2021 American Society of Breast Surgeons Annual Meeting.1 Findings from the retrospective...
Does the Addition of Bevacizumab to Gemcitabine/Cisplatin for Metastatic Urothelial Carcinoma Improve Survival?
As reported in the Journal of Clinical Oncology by Jonathan E. Rosenberg, MD, and colleagues, the phase III CALGB 90601/Alliance trial has shown no improvement in overall survival with the addition of bevacizumab to gemcitabine/cisplatin in patients with metastatic urothelial carcinoma. Study...
Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma
On February 5, 2021, lisocabtagene maraleucel was approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from...
FDA Approves Piflufolastat F-18 Injection, a PSMA PET Imaging Agent, for the Detection of Metastatic or Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved piflufolastat F-18 injection (Pylarify), an F-18–labeled prostate-specific membrane antigen (PSMA)-targeted positron-emission tomography (PET) imaging agent, to identify suspected metastasis or recurrence of prostate cancer. This is...
School-Based HPV Vaccination Program Reduces Rates of HPV in Gay and Bisexual Men
An Australian study published by Chow et al in The Lancet Infectious Diseases found a 70% reduction in one type of human papillomavirus (HPV) in gay and bisexual men after the implementation of the school-based HPV vaccination program. The HYPER2 study found that there was a significant reduction...
AUA Announces Updates to Clinical Guidance for Renal Mass and Localized Renal Cancer
The American Urological Association (AUA) announced amendments to its clinical guideline on Renal Masses and Localized Renal Cancer, originally published in 2013 and updated in 2017, based on an additional literature search conducted through October 2020. One in four renal masses are benign;...
Cemiplimab-rwlc for Patients With Locally Advanced Basal Cell Carcinoma After Hedgehog Inhibitor Therapy
As reported in The Lancet Oncology by Stratigos et al, findings in a subgroup of a phase II trial have shown that the PD-1 antibody cemiplimab-rwlc produces enduring responses in patients with locally advanced basal cell carcinoma who had progressive disease on or intolerance to prior hedgehog...
Use of Systemic Therapy at the End of Life in Patients With Cancer: Effect of Approval of Immunotherapies
In a study reported in JCO Oncology Practice, Khaki et al found that although the use of anticancer systemic therapy during the last 30 days of life in patients with cancer has decreased overall since the first approval of a PD-1 immune checkpoint inhibitor, the use of PD-1 or PD-L1 inhibitors...
Effect of Lower Endoscopy on Colorectal Cancer Incidence and Mortality in Individuals Older Than 75
In a prospective cohort study reported in JAMA Oncology, Ma et al found that lower endoscopy colorectal cancer screening in individuals older than age 75 was associated with reduced colorectal cancer incidence and mortality, although no colorectal cancer mortality benefit was observed in those with ...
Actionable Mutations Identified in Majority of Genome-Sequenced Resected Cholangiocarcinomas
Tumor genomic profiling of resected cholangiocarcinomas may reveal mutations targetable with agents currently being used for other cancers, according to the results of a study presented at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care.1 Among patients...
Perioperative Systemic Therapy for Patients With Resectable Colorectal Peritoneal Metastases
In the phase II portion of a Dutch phase II/III trial (CAIRO6) reported in JAMA Surgery, Rovers et al found that the addition of perioperative systemic therapy to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) was feasible and safe for the treatment of patients with ...
Oncology Hospital-at-Home Program Reduced Unplanned Health-Care Utilization and Costs
In the Huntsman at Home Real-World Trial reported in the Journal of Clinical Oncology, Mooney et al found that an oncology hospital-at-home program reduced unplanned health-care utilization and costs vs usual care among patients with cancer discharged from the hospital. Study Details In the study, ...
Lustgarten Foundation–AACR Career Development Awards for Pancreatic Cancer Research
Dannielle Engle, PhD, of the Salk Institute for Biological Studies, and Avery D. Posey, PhD, of the Perelman School of Medicine at the University of Pennsylvania, were announced at the American Association for Cancer Research (AACR) Annual Meeting 2021 as the inaugural recipients of the Lustgarten...
Enduring Cancer and Its Treatment With Resilience and Humor
Most cancer memoirs have a similar thread: life suddenly interrupted by arguably the three most dreaded words in the English language, “You have cancer.” Readers anticipate the high-drama uncertainty leading to diagnosis, treatment, and hopefully survivorship, with multiple human storylines woven...
A Seasoned Journalist Seeking Answers Reports From the Front Lines of the COVID-19 Pandemic
The COVID-19 pandemic remains a global health issue, putting unprecedented stress on health-care systems, with important implications for cancer care. Although at this stage the data are fairly limited, we know that patients with cancer are far more vulnerable to worse outcomes, including a greater ...
Coagulopathy and COVID-19 Infection
“Life is short, art long, opportunity fleeting, experience treacherous, judgment difficult.” —Hippocrates To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the...
Agnes Witkiewicz, MD, to Lead Roswell Park’s Cancer Genetics and Genomics Department
Roswell Park Comprehensive Cancer Center has appointed Agnes Witkiewicz, MD, as Director of Cancer Genetics and Genomics. She will also hold the John & Santa Palisano Endowed Chair of Cancer Genetics. An internationally recognized clinician-scientist who combines groundbreaking laboratory...
Balancing a Reverence for Life With a Belief That Patients Have a Right to a Dignified Death
The U.S. right-to-die movement took root in the mid-1970s, when Derek Humphry helped his wife, who was dying of breast cancer, take her own life. Five years later, Mr. Humphry founded the Hemlock Society, the first right-to-die organization in the United States,1 and set off a firestorm of...
Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
On March 26, 2021, idecabtagene vicleucel was approved for the treatment of adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.1,2 Idecabtagene vicleucel is...
An Epiphany During Fellowship Led to a Career in Geriatric Oncology for Heidi D. Klepin, MD, MS
Geriatric oncologist Heidi D. Klepin, MD, MS, was born and reared in Pearl River, a hamlet on the west side of the Hudson River in New York. “My parents are German immigrants who came to the United States in the 1960s looking for prospects. Growing up in post-war Germany, neither had the...
Refining Cardiovascular Risk Assessment in Childhood Cancer Survivors
There are an estimated 500,000 childhood cancer survivors in the United States, a number that will increase exponentially in the coming years. Over half of all childhood cancer survivors will have received cardiotoxic therapies during primary cancer treatment or relapse. For these survivors, there...
Improving Prediction of Risk for 10-Year Left-Ventricular Systolic Dysfunction in Survivors of Childhood Cancer
In a Dutch study reported in JACC: CardioOncology, Jan M. Leerink, PhD candidate, of Amsterdam UMC, University of Amsterdam Department of Clinical and Experimental Cardiology, and colleagues found that the addition of ejection fraction measurement at the time of first surveillance echocardiogram...
Sloan Kettering Institute Researchers Awarded 2021 Kravis Women in Science Endeavor Fellowship Grants
Memorial Sloan kettering Cancer Center (MSK) announced that Sloan Kettering Institute (SKI) researchers Regina Bou Puerto and Mijin Kim, PhD, have been named 2021 Marie-Josée Kravis Women in Science Endeavor (Kravis WiSE) fellowship grant recipients. The Kravis WiSE initiative, created in 2020,...
Celebrating 50 Years of Cancer Progress: The International View
Although the National Cancer Act of 1971 has resulted in tremendous advances in cancer research, which have led to sharp declines in cancer mortality in the United States—from 1991 to 2018, there has been a 31% decrease in overall cancer death rates—and more than 17 million cancer survivors,1 much...
Roswell Park, Wilmot Cancer Institute Collaborate in Study of Immunotherapy for Black Patients With Cancer
A NEW COLLABORATION between two Western New York cancer research leaders will help oncologists learn whether Black and White patients with cancer respond differently to immunotherapy and seek to improve the safety and effectiveness of these newer drugs in diverse populations. Funded by a 2-year,...
Nima Sharifi, MD, Receives 2021 AACR–Waun Ki Hong Award in Translational and Clinical Cancer Research
THE AMERICAN ASSOCIATION for Cancer Research (AACR) has recognized Nima Sharifi, MD, with the 2021 AACR–Waun Ki Hong Award for Outstanding Achievement in Translational and Clinical Cancer Research. Dr. Sharifi is Director of the Center for Genitourinary Malignancies Research at Lerner Research...
Stand Up To Cancer Funds $6 Million for Disparities in Cancer Clinical Trials Research
STAND UP TO CANCER® (SU2C) has awarded $6 million to a multi-institutional team headed by Mount Sinai researchers to collaborate with other New York institutions in an initiative that addresses disparities in cancer clinical trials participation by patients who are Black, indigenous, and people of...
Fam-trastuzumab Deruxtecan-nxki for Trastuzumab-Pretreated Advanced HER2-Positive Gastric Adenocarcinoma
On January 15, 2021, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki was approved for treatment of adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal adenocarcinoma who have received a prior trastuzumab-based regimen.1,2 Supporting Efficacy Data...
EMPOWER-Lung 1 Trial: New Options, No New Answers
The EMPOWER-Lung 1 trial, recently reported in The Lancet and reviewed in this issue of The ASCO Post, showed an improvement in progression-free and overall survival with cemiplimab-rwlc in patients with advanced non–small cell lung cancer (NSCLC) and high PD-L1 expression (tumor proportion score...
First-Line Cemiplimab-rwlc Improves Outcomes vs Platinum-Doublet Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 50%
As reported in The Lancet by Ahmet Sezer, MD, of Başkent University, Adana, Turkey, and colleagues, the phase III EMPOWER-Lung 1 trial has shown improved overall and progression-free survival with cemiplimab-rwlc vs platinum doublet chemotherapy among patients with advanced non–small cell lung...
FDA ODAC Meeting Focuses on ‘Dangling’ Accelerated Approvals of Anti–PD-1/PD-L1 Antibodies
In a perspective in The New England Journal of Medicine, Julia A. Beaver, MD, and Richard Pazdur, MD, of the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE), discussed issues surrounding “dangling” accelerated approvals of anti–PD-1/PD-L1 antibodies—ie, approvals for...
